Analysis of virus and host factors in a study of A/Peking/2/79 (H3N2) cold-adapted vaccine recombinant in which vaccine-associated illness occurred in normal volunteers.
Identifieur interne : 000424 ( PubMed/Checkpoint ); précédent : 000423; suivant : 000425Analysis of virus and host factors in a study of A/Peking/2/79 (H3N2) cold-adapted vaccine recombinant in which vaccine-associated illness occurred in normal volunteers.
Auteurs : R F Betts [États-Unis] ; R G Douglas ; H F Maassab ; D C Deborde ; M L Clements ; B R MurphySource :
- Journal of medical virology [ 0146-6615 ] ; 1988.
Descripteurs français
- KwdFr :
- MESH :
- effets indésirables : Vaccins antigrippaux, Vaccins atténués, Vaccins synthétiques.
- microbiologie : Partie nasale du pharynx.
- épidémiologie : Grippe humaine.
- étiologie : Grippe humaine.
- Adulte, Humains, Relation dose-effet des médicaments.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Influenza Vaccines, Vaccines, Attenuated, Vaccines, Synthetic.
- epidemiology : Influenza, Human.
- etiology : Influenza, Human.
- microbiology : Nasopharynx.
- Adult, Dose-Response Relationship, Drug, Humans.
Abstract
Live attenuated cold-adapted influenza vaccine is undergoing evaluation in man. Several strains have proven to be safe, immunogenic, nontransmissible, and protective against experimental challenge. In this study of A/Peking/2/79(H3N2), with six internal genes from the cold-adapted (Ca) parent A/Ann Arbor/6/60(H2N2), we encountered at the highest input multiplicity, 28% illness rate among individuals infected with vaccine. Reversion to wild type and excessive viral replication did not occur. Physical characteristics of the vaccine were similar to nonreactogenic vaccine A/Washington/897/80(H3N2). At ten- and 100-fold lower input multiplicities, infection frequency was maintained, but reactions did not occur. We compared the observations in this study with those made in a similar study of A/Scotland/840/74(H3N2), a cold-adapted vaccine with five genes from the Ca parent in which reactogenicity also was noted. The dose of vaccine virus in relation to tissue culture infectious doses required to infect 50% of susceptibles (HID50) was proportionally lower for both A/Peking/2/79(H3N2) and A/Scotland/80(H3N2). Hence, when the vaccine was undiluted the recipients were inoculated with more than 100 HID50. We concluded that the very high input could be avoided if vaccines were screened beginning at 1/1,000 of maximum titers. Ca vaccines must be safe before they undergo field trials.
DOI: 10.1002/jmv.1890260209
PubMed: 3183640
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:3183640Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Analysis of virus and host factors in a study of A/Peking/2/79 (H3N2) cold-adapted vaccine recombinant in which vaccine-associated illness occurred in normal volunteers.</title><author><name sortKey="Betts, R F" sort="Betts, R F" uniqKey="Betts R" first="R F" last="Betts">R F Betts</name><affiliation wicri:level="2"><nlm:affiliation>Infectious Disease Unit, University of Rochester, New York 14642.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Infectious Disease Unit, University of Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Douglas, R G" sort="Douglas, R G" uniqKey="Douglas R" first="R G" last="Douglas">R G Douglas</name></author><author><name sortKey="Maassab, H F" sort="Maassab, H F" uniqKey="Maassab H" first="H F" last="Maassab">H F Maassab</name></author><author><name sortKey="Deborde, D C" sort="Deborde, D C" uniqKey="Deborde D" first="D C" last="Deborde">D C Deborde</name></author><author><name sortKey="Clements, M L" sort="Clements, M L" uniqKey="Clements M" first="M L" last="Clements">M L Clements</name></author><author><name sortKey="Murphy, B R" sort="Murphy, B R" uniqKey="Murphy B" first="B R" last="Murphy">B R Murphy</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1988">1988</date><idno type="RBID">pubmed:3183640</idno><idno type="pmid">3183640</idno><idno type="doi">10.1002/jmv.1890260209</idno><idno type="wicri:Area/PubMed/Corpus">000470</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000470</idno><idno type="wicri:Area/PubMed/Curation">000470</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000470</idno><idno type="wicri:Area/PubMed/Checkpoint">000424</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000424</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Analysis of virus and host factors in a study of A/Peking/2/79 (H3N2) cold-adapted vaccine recombinant in which vaccine-associated illness occurred in normal volunteers.</title><author><name sortKey="Betts, R F" sort="Betts, R F" uniqKey="Betts R" first="R F" last="Betts">R F Betts</name><affiliation wicri:level="2"><nlm:affiliation>Infectious Disease Unit, University of Rochester, New York 14642.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Infectious Disease Unit, University of Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Douglas, R G" sort="Douglas, R G" uniqKey="Douglas R" first="R G" last="Douglas">R G Douglas</name></author><author><name sortKey="Maassab, H F" sort="Maassab, H F" uniqKey="Maassab H" first="H F" last="Maassab">H F Maassab</name></author><author><name sortKey="Deborde, D C" sort="Deborde, D C" uniqKey="Deborde D" first="D C" last="Deborde">D C Deborde</name></author><author><name sortKey="Clements, M L" sort="Clements, M L" uniqKey="Clements M" first="M L" last="Clements">M L Clements</name></author><author><name sortKey="Murphy, B R" sort="Murphy, B R" uniqKey="Murphy B" first="B R" last="Murphy">B R Murphy</name></author></analytic><series><title level="j">Journal of medical virology</title><idno type="ISSN">0146-6615</idno><imprint><date when="1988" type="published">1988</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Dose-Response Relationship, Drug</term><term>Humans</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (etiology)</term><term>Nasopharynx (microbiology)</term><term>Vaccines, Attenuated (adverse effects)</term><term>Vaccines, Synthetic (adverse effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Grippe humaine (épidémiologie)</term><term>Grippe humaine (étiologie)</term><term>Humains</term><term>Partie nasale du pharynx (microbiologie)</term><term>Relation dose-effet des médicaments</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Vaccins atténués (effets indésirables)</term><term>Vaccins synthétiques (effets indésirables)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Attenuated</term><term>Vaccines, Synthetic</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins atténués</term><term>Vaccins synthétiques</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Partie nasale du pharynx</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Nasopharynx</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Dose-Response Relationship, Drug</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Humains</term><term>Relation dose-effet des médicaments</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Live attenuated cold-adapted influenza vaccine is undergoing evaluation in man. Several strains have proven to be safe, immunogenic, nontransmissible, and protective against experimental challenge. In this study of A/Peking/2/79(H3N2), with six internal genes from the cold-adapted (Ca) parent A/Ann Arbor/6/60(H2N2), we encountered at the highest input multiplicity, 28% illness rate among individuals infected with vaccine. Reversion to wild type and excessive viral replication did not occur. Physical characteristics of the vaccine were similar to nonreactogenic vaccine A/Washington/897/80(H3N2). At ten- and 100-fold lower input multiplicities, infection frequency was maintained, but reactions did not occur. We compared the observations in this study with those made in a similar study of A/Scotland/840/74(H3N2), a cold-adapted vaccine with five genes from the Ca parent in which reactogenicity also was noted. The dose of vaccine virus in relation to tissue culture infectious doses required to infect 50% of susceptibles (HID50) was proportionally lower for both A/Peking/2/79(H3N2) and A/Scotland/80(H3N2). Hence, when the vaccine was undiluted the recipients were inoculated with more than 100 HID50. We concluded that the very high input could be avoided if vaccines were screened beginning at 1/1,000 of maximum titers. Ca vaccines must be safe before they undergo field trials.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3183640</PMID><DateCompleted><Year>1988</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0146-6615</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>2</Issue><PubDate><Year>1988</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J. Med. Virol.</ISOAbbreviation></Journal><ArticleTitle>Analysis of virus and host factors in a study of A/Peking/2/79 (H3N2) cold-adapted vaccine recombinant in which vaccine-associated illness occurred in normal volunteers.</ArticleTitle><Pagination><MedlinePgn>175-83</MedlinePgn></Pagination><Abstract><AbstractText>Live attenuated cold-adapted influenza vaccine is undergoing evaluation in man. Several strains have proven to be safe, immunogenic, nontransmissible, and protective against experimental challenge. In this study of A/Peking/2/79(H3N2), with six internal genes from the cold-adapted (Ca) parent A/Ann Arbor/6/60(H2N2), we encountered at the highest input multiplicity, 28% illness rate among individuals infected with vaccine. Reversion to wild type and excessive viral replication did not occur. Physical characteristics of the vaccine were similar to nonreactogenic vaccine A/Washington/897/80(H3N2). At ten- and 100-fold lower input multiplicities, infection frequency was maintained, but reactions did not occur. We compared the observations in this study with those made in a similar study of A/Scotland/840/74(H3N2), a cold-adapted vaccine with five genes from the Ca parent in which reactogenicity also was noted. The dose of vaccine virus in relation to tissue culture infectious doses required to infect 50% of susceptibles (HID50) was proportionally lower for both A/Peking/2/79(H3N2) and A/Scotland/80(H3N2). Hence, when the vaccine was undiluted the recipients were inoculated with more than 100 HID50. We concluded that the very high input could be avoided if vaccines were screened beginning at 1/1,000 of maximum titers. Ca vaccines must be safe before they undergo field trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Betts</LastName><ForeName>R F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Infectious Disease Unit, University of Rochester, New York 14642.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Douglas</LastName><ForeName>R G</ForeName><Initials>RG</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Maassab</LastName><ForeName>H F</ForeName><Initials>HF</Initials></Author><Author ValidYN="Y"><LastName>DeBorde</LastName><ForeName>D C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Clements</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>B R</ForeName><Initials>BR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>N01-AI-02653</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-AI-12666</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-AI-72521</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009305" MajorTopicYN="N">Nasopharynx</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3183640</ArticleId><ArticleId IdType="doi">10.1002/jmv.1890260209</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><noCountry><name sortKey="Clements, M L" sort="Clements, M L" uniqKey="Clements M" first="M L" last="Clements">M L Clements</name><name sortKey="Deborde, D C" sort="Deborde, D C" uniqKey="Deborde D" first="D C" last="Deborde">D C Deborde</name><name sortKey="Douglas, R G" sort="Douglas, R G" uniqKey="Douglas R" first="R G" last="Douglas">R G Douglas</name><name sortKey="Maassab, H F" sort="Maassab, H F" uniqKey="Maassab H" first="H F" last="Maassab">H F Maassab</name><name sortKey="Murphy, B R" sort="Murphy, B R" uniqKey="Murphy B" first="B R" last="Murphy">B R Murphy</name></noCountry><country name="États-Unis"><region name="État de New York"><name sortKey="Betts, R F" sort="Betts, R F" uniqKey="Betts R" first="R F" last="Betts">R F Betts</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000424 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000424 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:3183640
|texte= Analysis of virus and host factors in a study of A/Peking/2/79 (H3N2) cold-adapted vaccine recombinant in which vaccine-associated illness occurred in normal volunteers.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:3183640" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |